Biogen, Isis unite for the 4th time to develop neurological drugs

09/10/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec signed a deal with Isis Pharmaceuticals to develop new treatments for neurological diseases using the latter's antisense technology. The current deal, which entitles Isis to $100 million upfront, is the fourth collaboration between the firms in the past two years. Isis will get milestone and licensing fees plus sales royalties on products arising from the collaboration.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY